Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by GrahamBon Dec 21, 2022 11:17am
81 Views
Post# 35184662

RE:RE:RE:RE:RE:RE:RE:RE:Q1 2023 will be the first quarter with the full sales 33

RE:RE:RE:RE:RE:RE:RE:RE:Q1 2023 will be the first quarter with the full sales 33

G1945V (290)

User Actions  

12 minutes ago

7 Reads

Post# 35184586

RE:RE:RE:RE:RE:RE:RE:Q1 2023 will be the first quarter with the full sales 33

 

“It makes it very hard to believe in anything you say. Your criticism on this forum and I'm sure on others focuses so much on this one little company, almost making it your life mission to put it down, to somehow be proven right to your listeners, but somewhat refuse to look at the big picture and this company's potential contribution to the medical industry when there is clear evidence it will do good. All you want to equate VPT with is sales when this company is trying to get off the ground when it went through so many trials and tribulations and still standing. Give it a break, will you? “

 

This is interesting.

You can’t believe because I post on facts about this company.

 

You are correct. I am relying on financial information to judge this company

This is a recognized, and proven approach to investing-even in small caps.

 

I think, thinking about this further, one of fundamental differences between us is that you are speculating, and I am investing. 

 

Thank you for the advice, but I will continue to post as I went to, in response to new data, and misinformation.

 

So view my posts as reactive 

Reactive to data and misinformation.

Again note that a cursory review of this board will show that poppers like Joe patch, post 10 to 15 times for every post that I make, and his posts are repetitive, and promotional. You see it fit never to comment on his, but always reliably to comment on mine 

This should tell you something

 

You are perfectly happy, to support this information, if it will meet your objective.

<< Previous
Bullboard Posts
Next >>